VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

MERS England1 S DNA + MERS England1 S protein subunit vaccine
Vaccine Information
  • Vaccine Name: MERS England1 S DNA + MERS England1 S protein subunit vaccine
  • Target Pathogen: MERS-CoV
  • Target Disease: Middle East Respiratory Syndrome (MERS)
  • Type: Mixed, DNA vaccine and Subunit vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse, rhesus monkey
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: A mixed vaccine using England S1 subunit protein vaccine and England1 S DNA vaccine. VRC8400 plasmid used to construct antigen (Wang et al., 2015)
Host Response

Mouse Response

  • Host Strain: BALB/cJ
  • Host age: 6-8 weeks (Wang et al., 2015)
  • Host gender: Female (Wang et al., 2015)
  • Vaccination Protocol: S1 MERS-CoV full-length Spike protein at weeks and 3 and then injected with S1 protein plus Ribi adjuvant (Sigma-Aldrich, St. Louis, MO) at week 6 (Wang et al., 2015)
  • Immune Response: high titers of neutralizing antibody (Wang et al., 2015)
  • Challenge Protocol: Animals were challenged with JordanN3 strain of MERS-CoV (Wang et al., 2015)

Macaque Response

  • Host Strain: Macaca mulatta (Wang et al., 2015)
  • Host gender: Male and Female (Wang et al., 2015)
  • Vaccination Protocol: Six NHPs in the S DNA-S1 protein group were injected with 1 mg of plasmid DNA encoding MERS-CoV full-length Spike at weeks 0 and 4 and boosted with 100 μg of MERS-CoV S1 protein and AlPO4 adjuvant (Brenntag Biosector, Frederikssund, Denmark) at week 8 (Wang et al., 2015)
  • Challenge Protocol: challenged with Jordan N3 strain of MERS-CoV 19 weeks after immunization at 3.1e6, 3.6e6, and 3.4 e6 p.f.u. (Wang et al., 2015)
  • Efficacy: protected (Wang et al., 2015)
References
Wang et al., 2015: Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nature communications. 2015; 6; 7712. [PubMed: 26218507].